Emerson Electric Co

Emerson provides automation solutions and climate technologies, selling control systems, measurement instruments, valves, and actuators to industrial customers alongside HVAC and refrigeration equipment for commercial applications. The company earns revenue from selling hardware, software, and services to process manufacturers (chemicals, oil and gas, power generation), discrete manufacturers, and commercial building operators. Following recent restructuring, Emerson focuses on two platforms: Automation Solutions (process control systems for factories and plants) and Commercial & Residential Solutions (air conditioning, refrigeration compressors, and thermostats like Sensi and White-Rodgers brands).

Emerson benefits from industrial automation trends as manufacturers adopt digital technologies and pursue efficiency improvements. The installed base of process control systems generates recurring service and upgrade revenue. Climate technologies benefit from HVAC replacement cycles and energy efficiency regulations. Risks include cyclical exposure to industrial capital expenditure cycles, energy sector volatility affecting oil and gas customers, competition from both specialized automation vendors and diversified industrial conglomerates, and execution challenges integrating recent acquisitions. The stock offers defensive industrial exposure with moderate growth, typically trading at mid-tier valuations within the automation sector.

In automation solutions, Honeywell, Schneider Electric, ABB, Siemens, and Rockwell Automation compete for process control and industrial automation spending. Yokogawa competes in measurement and control instrumentation. In commercial HVAC, Carrier Global, Trane Technologies, and Johnson Controls offer competing climate control systems. For refrigeration compressors, Danfoss and Carrier are key rivals. The competitive landscape varies significantly between automation (fragmented with multiple specialists) and climate technologies (more consolidated among major HVAC players).

Emerson has paid consecutive quarterly dividends for over 65 years and raised the dividend annually for more than six decades, qualifying as a dividend king. The current yield runs approximately 1.5%, supported by consistent cash flow generation. The payout ratio typically runs around 50-60% of earnings, balancing income distributions with investments in automation technology and strategic acquisitions. Despite recent portfolio restructuring and cyclical industrial markets, Emerson has maintained its dividend growth streak, making it attractive to income investors seeking reliable long-term dividend growth from industrial exposure.

EMR last closed at $130.86, up 0.55% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $90.06 and a high of $165.15. The current price represents 54% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 35 analysts covering EMR, the consensus rating is Buy — 24 rate it a buy, 10 hold, and 1 sell. The average price target sits at $120.06, implying 8% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Emerson Electric Co generated $17.97B in revenue during fiscal year 2026, with $2.29B reaching the bottom line as net income. The net profit margin of 12.7% is solid for its sector.

EMR trades at a P/E ratio of 33.84 on trailing earnings of $4.09 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Electrical Equipment sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -3.57% (3M), +1.25% (6M), +15.20% (1Y), -3.65% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether EMR is outperforming or lagging the broader market.